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Abstract
Background: Recently, tissue engineering has merged with stem cell technology with interest to develop
new sources of transplantable material for injury or disease treatment. Eminently interesting, are bone and
joint injuries/disorders because of the low self-regenerating capacity of the matrix secreting cells,
particularly chondrocytes. ES cells have the unlimited capacity to self-renew and maintain their
pluripotency in culture. Upon induction of various signals they will then differentiate into distinctive cell
types such as neurons, cardiomyocytes and osteoblasts.
Results: We present here that BMP-2 can drive ES cells to the cartilage, osteoblast or adipogenic fate
depending on supplementary co-factors. TGFβ1, insulin and ascorbic acid were identified as signals that
together with BMP-2 induce a chondrocytic phenotype that is characterized by increased expression of
cartilage marker genes in a timely co-ordinated fashion. Expression of collagen type IIB and aggrecan,
indicative of a fully mature state, continuously ascend until reaching a peak at day 32 of culture to
approximately 80-fold over control values. Sox9 and scleraxis, cartilage specific transcription factors, are
highly expressed at very early stages and show decreased expression over the time course of EB
differentiation. Some smaller proteoglycans, such as decorin and biglycan, are expressed at earlier stages.
Overall, proteoglycan biosynthesis is up-regulated 7-fold in response to the supplements added. BMP-2
induced chondrocytes undergo hypertrophy and begin to alter their expression profile towards
osteoblasts. Supplying mineralization factors such as β-glycerophosphate and vitamin D3 with the culture
medium can facilitate this process. Moreover, gene expression studies show that adipocytes can also
differentiate from BMP-2 treated ES cells.
Conclusions: Ultimately, we have found that ES cells can be successfully triggered to differentiate into
chondrocyte-like cells, which can further alter their fate to become hypertrophic, and adipocytes.
Compared with previous reports using a brief BMP-2 supplementation early in differentiation, prolonged
exposure increased chondrogenic output, while supplementation with insulin and ascorbic acid prevented
dedifferentiation. These results provide a foundation for the use of ES cells as a potential therapy in joint
injury and disease.
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Articular cartilage is composed of extracellular matrix
(ECM), the matrix-secreting chondrocyte and water,
which all account for the tissue's characteristic rigidity as
well as its flexibility. These features are necessary in order
to warrant life-long survival of the cartilage tissue, espe-
cially in the joint where it has to endure pressure forces
caused by movement. Chondrocytes arise from a mesen-
chymal progenitor during development, the same progen-
itor that gives rise to other mesenchymal cell types
including osteoblasts, adipocytes and myocytes. Bone for-
mation can either be endochondral, when chondrocytes
mature and calcify to provide a matrix for the invading
osteoprogenitors, or intramembraneous involving ossifi-
cation directly from a mesenchymal ancestor. All these
diverse cell types may arise from the same precursor, but
are distinguished by specific morphological features and
with that, a certain set of characteristic proteins including
transcription factors that control their differentiation.
Two chondrocyte-specific transcription factors have been
identified, Sox9, a member of the SOX-family of transcrip-
tion factors, and Scleraxis, a member of the basic helix-
loop-helix transcription factors [1,2]. However, most of
the exclusive markers for cartilage tissue reside in the
ECM. The predominant form of collagen in mature carti-
lage is collagen type IIB, whereas the alternatively spliced
collagen IIA is found primarily during development [3].
Aggrecan is the major proteoglycan species in cartilage [4].
The transition of chondrocytes into hypertrophy is distin-
guished by a change in expression of Cbfa1, the osteob-
last-specific transcription factor, which is also switched on
during intramembraneous ossification. Distinctive to car-
tilage, the major collagen molecule in osseus matrix is col-
lagen type I. In contrast, the transcription factors
controlling adipogenesis are C/EBPα and PPARγ, which
transactivate subsets of genes as a function of either trans-
acting factor alone or requiring the co-operative effort of
both [5]. C/EBPα is known to bind to and transactivate
particularly the promotors of the SCD1, aP2 and the
Glut4 genes [6,7], all highly characteristic of the adipocyte
phenotype.
For decades, the treatment of degenerative cartilage and
bone diseases has been a challenge for orthopaedic sur-
geons due to the apparent inability of cartilage and bone
to repair itself. Arthritis, a degenerative joint condition, is
one of the most prevalent chronic health conditions in
North America. Arthritis can devastate people, but to date
there is no effective therapy available and patients can
only be helped by surgical joint replacement. An inherent
major concern is the limited availability of autografts,
which significantly reduces the choice of treatable defects.
However, new approaches to cell grafting are being devel-
oped in this field: increased yields of cells are achieved by
the usage of bioreactors and growth factor administration,
such as TGFβ1 and BMPs [8,9]. Additionally, stem cells are
being discovered as a new source of transplantable
material.
Embryonic stem cells represent a valuable source for cell
transplantation since their characteristic features include
an unlimited self-renewing capacity and a multilineage
differentiation potential [10,11]. In fact, ES-derived glial
precursors and cardiomyocytes have been successfully
transplanted, integrated and shown to be functionally
active in the transplantation site [12,13]. The yield of dif-
ferentiation of ES cells into an intended lineage can be
greatly enhanced by the addition of growth factors or
induction substances. Whereas protocols for the differen-
tiation of cardiomyocytes, neuronal cell types, insulin-
producing cells or adipocytes from ES cells have been
available for many years [14-17], only recently their differ-
entiation into elements of the skeleton has been reported
[18-20]. Our group has previously shown that vitamin D3
forces ES cells to undergo osteogenesis [18]. Kramer et al.
have reported in 2000 that BMP-2 pushes ES cells to the
chondrogenic fate when added during days 3–5 of EB dif-
ferentiation [21]. Those ES-derived chondrocytes possess
a certain plasticity to undergo hypertrophy and calcify
[22].
We show here, that prolonged treatment of differentiating
ES cell cultures with BMP-2 in synergy with TGFβ1, insulin
and ascorbic acid leads to improved chondrogenesis in
vitro. Compared to the brief supplementation described
by Kramer et al. [21], the expression of chondrocyte-spe-
cific marker genes was highly up-regulated while prote-
oglycan content revealed an increased chondrocytic yield
from 7.26% to 57.03%. As described by other groups [22],
ES-derived chondrocytes become hypertrophic and cal-
cify. However, spontaneous calcification did not reach
mineralization levels that are found in vitamin D3
induced ES-derived osteoblasts [18]. Yet, supplementa-
tion of chondrocyte-cultures with β-glycerophosphate,
ascorbic acid and vitamin D3 starting at day 20 rescued the
osteoblast phenotype. In many differentiations, we also
observed an accumulation of lipid droplets and an up-reg-
ulation of adipocyte-specific genes. This direction towards
adipocyte differentiation varied with the use of specific
co-factors, suggesting that in the future, such spurious dif-
ferentiation may be controlled, once the pathways
involved in adipogenesis are better understood.
Results
Characterization of chondrocyte-like cells derived from ES 
cells
Embryonic stem cell cultures supplemented with BMP-2,
TGFβ1, insulin and ascorbic acid show typical morpholog-
ical changes compared to the untreated cultures. StartingPage 2 of 15
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BMC Developmental Biology 2005, 5:1 http://www.biomedcentral.com/1471-213X/5/1Morphology and characteristics of ES-derived chondrocytes after 32 days of cultureFigure 1
Morphology and characteristics of ES-derived chondrocytes after 32 days of culture. (A, B) Determination of proteoglycans in 
EBs with alcian blue in chondrocyte cultures induced with TGFβ1 [2 ng/ml] and BMP-2 [10 ng/ml] from d3–5 of culture and 
with BMP-2 [10 ng/ml], ascorbic acid [50 µg/ml] and insulin [1 µg/ml] from day 5 onwards (A) compared to control cultures 
(B). Bar = 8.3 µm. (C, D) Analysis of cartilage-specific matrix proteins in 32 day old EBs induced with the same supplements as 
in (A, B) by means of immunohistochemistry. Staining with anti-collagen type II (C) and anti-cartilage proteoglycan (D), respec-
tively, both visualized by a secondary AlexaFluor 488 conjugated antibody. Bar = 106 µm. (E) Concentration-dependent effect 
of BMP-2 on chondrocyte-specific gene expression in 32-day old EBs. Values of cultures supplemented with 10 ng/ml BMP-2 
are shown compared to 2 ng/ml as used by Kramer et al. [2000], which was set as 1. Values represent means of three inde-
pendent experiments ± standard deviation, obtained by quantitative RT-PCR analysis. **P < 0.01; ***P < 0.001. (F) Proteogly-
can content of EB extracts on day 32. BMP-2 directs increased proteoglycan synthesis in both 2 ng/ml and 10 ng/ml. *P < 0.1; 
**P < 0.01. Mean ± standard deviation, n = 3.Page 3 of 15
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small round cells formed in the supplemented cultures,
which stained positive with alcian blue (fig. 1A). Little
alcian blue staining was seen in control cultures (fig. 1B).
Polygonal cells, which could also be found in treated cul-
tures, did not stain with alcian blue. Significant immunos-
taining for the collagen type II (COL II) protein was
observed at day 32 in treated cultures corresponding to
the active secretion and formation of an extracellular
matrix found with chondrocytes. The COL II antibody
identified the fibrillary organization of the collagen mol-
ecules in the extracellular matrix (fig. 1C). Chondrogenic
differentiation was confirmed by positive immunostain-
ing for adult proteoglycans (fig. 1D), which is detectable
in the aggregates identified by alcian blue staining. The
distribution was associated with the extracellular matrix
similar to that found with the COL II antibody. Staining
appeared to be diffuse as extracellular matrix and not indi-
vidual cells are stained.
Dependence of gene expression patterns and 
proteoglycan synthesis on BMP-2
Quantitative RT-PCR was used to examine the variability
of RNA expression of various cartilage-specific genes in
response to BMP-2. Previously, chondrogenesis was
induced in ES cells using 2 ng/ml BMP-2 on days three to
five of EB formation, when early mesodermal markers
such as Brachyury and BMP-4 are expressed [21,23,24]. To
improve chondrogenesis, we investigated whether a
higher concentration of BMP-2 (10 ng/ml) could increase
chondrocyte-specific gene expression. Total RNA was
extracted on day 32 and quantitative real-time PCR was
carried out. Expression of genes of interest in cultures sup-
plemented with 10 ng/ml BMP-2 was normalized to
GAPDH expression and compared to cultures supple-
mented with 2 ng/ml (fig. 1E), which were set as 1. Expres-
sion of the small leucine-rich proteoglycans biglycan and
decorin was increased 1.6 fold upon supplementation
with 10 ng/ml BMP-2 (P < 0.01). Neither link protein
expression nor Sox9 or scleraxis expression were affected
by the higher dosage. However, expression of aggrecan
and the collagen type II isoforms A and B, which are spe-
cific for mature chondrocytes, were significantly increased
compared to the low BMP-2 concentration described by
Kramer et al. (P < 0.001). The degree of chondrogenic dif-
ferentiation under influence of BMP-2 was further quanti-
fied by metachromatic detection of proteoglycans (fig.
1F). Secreted proteoglycans were extracted on day 32 of
culture with guanidine/HCl and combined with dimeth-
ylmethylenblue. Based on our measurement of aggrecan,
the synthesis of proteoglycan proteins is also increased
under the influence of BMP-2. BMP-2 at 2 ng/ml initiated
an induction in proteoglycan synthesis of about 2 fold (P
< 0.01), whereas 10 ng/ml BMP-2 increased the proteogly-
can content of EBs 2.3 fold (P < 0.1) compared to non-
treated controls. This data shows, that BMP-2 causes the
induced synthesis of negatively charged extracellular
matrix, characterized by proteoglycans.
Additive effect of TGFβ1, insulin and ascorbic acid on BMP-
2 induced chondrogenesis
Since BMP-2 is believed to play a role in late chondrogen-
esis [25], we studied the effect of prolonged BMP-2 sup-
plementation beyond day 5 of culture. Additionally, the
anabolic effect of insulin and ascorbic acid and the influ-
ence of the growth factor TGFβ1 on BMP-2 induced differ-
entiation was determined quantitatively by PCR analysis
at various stages throughout EB differentiation. Table 1
shows the particular combinations of medium supple-
ments used at different culture stages of the 'hanging drop'
protocol used for differentiation, in which day 1–3 repre-
sent the hanging drop stage. During days 3–5 the resulting
embryoid bodies are cultured in suspension and then
plated onto tissue culture treated plastic ware on day 5.
Applied concentrations were 10 ng/ml BMP-2, 2 ng/ml
TGFβ1, 1 µg/ml insulin and 50 µg/ml ascorbic acid. Dex-
amethasone, which is also known to be a chondro-induc-
ing agent [26], did not evoke a mentionable chondrogenic
response in the D3 ES cell line (data not shown). Figure 2
shows changes in cartilage-specific gene expression under
the influence of various differentiation co-factors
throughout the 32 days of culture. TGFβ1 (combination B)
evoked a 2-fold increase in collagen II expression for both
splice forms. The synergistic effect of both growth factors,
TGFβ1 and BMP-2 (combination C) began to show an
increased expressions of aggrecan, link protein and COL
IIA compared to cultures that were treated with one sup-
plement alone. Additional supplementation with insulin
and ascorbic acid between culture days 3 and 5 (combina-
tion D) barely increased aggrecan, link protein and COL II
expression, but when given from day 5 onwards enhanced
both the BMP-2 and TGFβ1 effects (supplement combina-
tions E and H). Addition of insulin and ascorbic acid to
BMP-2 induced cultures increased collagen type IIA and
aggrecan expression minimally to 1.2-fold, link protein
and collagen type IIB were induced 2.7- to 2.8-fold com-
pared to BMP-2 alone. The TGFβ1 response was increased
3- to 4-fold. When cultures were induced with BMP-2 and
TGFβ1 in suspension (d3–5) and supplemented with insu-
lin and ascorbic acid starting on day 5 onwards (combina-
tion F), aggrecan, link protein and COL II were up-
regulated 10-fold compared to controls.
Surprisingly, when BMP-2 supplementation was main-
tained throughout the culture period (combination G), a
dramatic increase of marker gene expression was seen.
Aggrecan and COL IIB were up-regulated over 80-fold
above controls and link protein and COL IIA expression
was increased to 35- and 16-fold, respectively. Here, scle-
raxis and Sox9 expression behaved conversely.Page 4 of 15
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of scleraxis and Sox9 expression to 50 and 87% of the con-
trol, respectively (P = 0.001). Deferral of the expression of
these transcription factors in favour of chondrogenic dif-
ferentiation characterizes BMP-2 induced differentiation,
whereupon chondrogenic processes are furthermore
enhanced by TGFβ1, insulin and ascorbic acid.
The determination of proteoglycan content was used to
confirm the results obtained by quantitative RT-PCR for
all supplement combinations (fig. 2B). TGFβ1 alone
(combination B) did not alter proteoglycan levels com-
pared to controls, and in combination with BMP-2
decreased the proteoglycan content of EBs compared to
BMP-2 alone (combination C). Insulin and ascorbic acid
did not enhance the proteoglycan synthesis in combina-
tion with TGFβ1, but caused a 4.2-fold increase in combi-
nation with BMP-2 (combination E, P = 0.01). In
agreement with aggrecan gene expression, combinations F
and G generated a massive 7-fold induction of proteogly-
cans in EBs (P = 0.001).
Genetically manipulated ES cells that express GFP under
the control of chondrocyte-specific aggrecan promotor
were then used to quantify chondrocyte yield using fluo-
rescence-activated cell sorting. ES cells were differentiated
along the chondrocytic lineage using BMP-2 at 2 ng/ml or
supplement combination G [d3–5: TGFβ1 10 ng/ml, BMP-
2 10 ng/ml; d3–32: BMP-2 10 ng/ml, ascorbic acid 50 µg/
ml and insulin 1 µg/ml]. Green fluorescing chondrocytes
in both cultures appeared either organized in clusters or
scattered as seen in figure 3A. The Kramer protocol gave a
7.26 percent yield of chondrocytes, which was increased
to 57.03% using our modified protocol (fig. 3B).
Kinetic analysis of cartilage-specific gene expression 
during EB differentiation
The degree of chondrogenic differentiation using BMP-2,
TGFβ1, insulin and ascorbic acid supplementation was
then examined over the 35-day culture period using quan-
titative RT-PCR of various cartilage matrix genes (fig. 4).
Since the extent of changes in cartilage-specific genes
seemed to be dependent on acute (d 3–5) or chronic (d 3–
32) application of BMP-2 (supplement combination F
versus supplement combination G), the stronger induc-
tion by chronic supplementation of BMP-2 was moni-
tored throughout the culture duration. During the first
three weeks of the BMP-2 induced differentiation, only
minor changes in aggrecan, link protein or collagen type
II expression could be detected. Starting with day 26 how-
ever, aggrecan expression was up-regulated significantly to
14-fold over control niveaus (P < 0.1). Reaching day 32,
aggrecan, link protein and collagen type II A and B
approached peak levels. Consistent with the aggrecan
expression profile, link protein expression was found to
be significantly up-regulated on days 24–27 (factor 6.3; P
= 0.001). Increased values were detectable as early as day
16. On day 26, the quantification of the collagen type IIA
and B showed 11- and 24-fold increases respectively. On
day 14, splice form B had already reached an 8-fold
increase over control values. In contrast, during the early
phases of differentiation, between day 5 and 20, collagen
type IIA expression was continuously increased 2-fold.
Transcripts for biglycan and decorin were detectable
throughout all stages of chondrogenic differentiation.
With the beginning of the maturation phase in the fourth
week of culture (day 21–28), both genes were up-regu-
lated 1.5–2 fold. Transcription factors scleraxis and Sox9
(fig. 4B) showed a similar expression profile constantly
over the entire culture period. This level did not change
significantly during chondrogenic differentiation, but
rather decreased compared to controls. Both were already
transcribed in day 5 EBs, hallmarking their participation
in early differentiation events, where lineage specificity is
determined. Additionally, scleraxis transcripts were
engaged in later phases of development between days 16–
19. Sox9 expression was also increased between days 9–11
and between days 25–27. In conclusion, cultures supple-
mented with BMP-2, TGFβ1, insulin and ascorbic acid
express mRNAs of a chondrogenic phenotype, whose
expression was time-dependent.
ES-derived chondrocytes undergo hypertrophy and 
mineralize
During embryo development endochondral ossification
occurs in two steps: chondrocytes arise after mesenchymal
Table 1: Combinations of medium supplements used at different 
culture stages
Supplement 
combination
Day 3–5 
(hanging drops)
Day 5 onwards 
(attached culture)
A BMP-2
B TGFβ1
C BMP-2
TGFβ1
D BMP-2
TGFβ1
insulin
ascorbic acid
E BMP-2 insulin
ascorbic acid
F BMP-2
TGFβ1
insulin
ascorbic acid
G BMP-2
TGFβ1
insulin
ascorbic acid
BMP-2
H TGFβ1 insulin
ascorbic acid
Applied concentrations were 10 ng/ml BMP-2, 2 ng/v ml TGFβ1, 1 µg/
ml insulin and 50 µg/ml ascorbic acid. The end of the culture period 
varied with every experiment carried out.Page 5 of 15
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expression of collagen type X, and calcification. To test
whether this was true for the ES-derived chondrocytes
generated with our protocol, we assayed for the Ca2+ con-
tent of the cultures, a measure for mineralization (fig. 5A).
Calcium was increased 1.2-fold in cells that were supple-
mented with BMP-2, TGFβ1, insulin and ascorbic acid
compared to controls (P < 0.01). Previously, we have
described the induction of mineralization in osteoblasts
derived from ES cells with vitamin D3, which reach matu-
rity at day 32 of culture [18,27]. Here, we observed that
the level of mineralization was considerably higher in
direct osteoblast differentiation [11.57 mg/dl] compared
to indirect differentiation using our improved chondro-
cyte protocol [3.22 mg/dl]. We observed, however, that
the level of calcium found in VD3 induced ES-derived
osteoblasts could be rescued in the chondrocytes by add-
ing VD3 on day 20 of differentiation, a time when
chondrocytes could be morphologically identified in the
cultures (11.18 mg/dl, P < 0.001). As shown by quantita-
tive RT-PCR, VD3 treated ES cell derived chondrocytes
could alter their expression profile to that of d32 ES cell
derived osteoblasts (fig. 5B). However, expression of oste-
ocalcin and bone sialoprotein was less than in VD3 res-
cued chondrocyte cultures than in VD3 osteoblast
cultures. Interestingly, chondrocyte-specific genes could
not be detected in VD3 osteoblasts and waned in VD3 res-
cued chondrocytes. As we have shown previously, ES-
derived mineralized osteocalcin expressing osteoblasts
can be identified as black appearing cells in phase contrast
microscopy [18]. Figure 5C shows these black cells in the
VD3 treated cultures. No such cells are visible in control
cultures or in ES-derived chondrocyte differentiations.
However, by adding VD3 back in at day 20 to the chondro-
Changes on cartilage markers in response to various combinations of BMP-2, TGFβ1, insulin and ascorbic acid as outlined in table 1Figur  2
Changes on cartilage markers in response to various combinations of BMP-2, TGFβ1, insulin and ascorbic acid as outlined in 
table 1. (A) Diagram of expression niveaus of cartilage-specific genes of 32 day old EBs obtained by quantitative RT-PCR and 
standardized to GAPDH. Untreated control values were set as 1. Mean ± standard deviation, n = 3. *P < 0.1; **P < 0.01; ***P 
= 0.001. (B) Proteoglycan content of extracts of 32 day old EBs treated with different combinations of BMP-2, TGFβ1, insulin 
and ascorbic acid (see table 1). Ctrl = control. Means ± standard deviation, n = 3. *P < 0.1; **P < 0.01; ***P = 0.001. n.d. = not 
determined.Page 6 of 15
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zation pattern is slightly different. These observations
support the hypothesis that VD3 induces intramembrane-
ous bone formation directly from mesenchymal progeni-
tors while BMP-2 controls endochondral bone formation.
It has been shown by others that the BMP-2 induced alter-
ation in cell fate is both concentration- and time-depend-
ent [28]. Lower concentrations of BMP-2 support
chondrogenesis whereas higher concentrations promote
osteogenesis. In ES cells, BMP-2 at concentrations of 2 ng/
ml, 10 ng/ml and 100 ng/ml did not increase the expres-
sion of bone markers with the exception of osteocalcin
and osteopontin, which were significantly increased as
shown by quantitative RT-PCR (fig. 6). In combination
with VD3 (given on days 5–30) however, alkaline phos-
phatase and Cbfa1 were also significantly up-regulated
above controls (5.4- and 4-2-fold, respectively, P < 0.001).
As we noted earlier, BMP-2 induced osteogenesis with or
without VD3 supplementation did not meet the levels that
were attained by VD3 alone, but the late addition of VD3
on day 20 rescued bone-specific gene expression arguing
for an involvement for BMP-2 in endochondral bone
formation.
Induction of adipocyte differentiation
During treatment of EBs with various chondrocyte differ-
entiation inducing factors, we noticed accumulation of
lipid droplets, which could not be found in untreated con-
trols. Those droplets could indeed be characterized as
Quantification of chondrogenic yield by flow cytometryFigure 3
Quantification of chondrogenic yield by flow cytometry. (A, B) Genetically modified ES cells expressing GFP from the chondro-
cyte-specific aggrecan promotor. Green fluorescing chondrocytes appear as clusters of cells within the remaining cell popula-
tion (A), but are also scattered in the entire population starting at day 28 of differentiation (B). (C) FACS analysis of ES-derived 
chondrocytes sorted by their GFP expression. Differentiation with BMP-2 only [2 ng/ml, d3–5] produced 7.26% GFP express-
ing cells compared to spontaneously differentiated controls, which contained very low levels of fluorescing cells (1.54%). Pro-
longed BMP-2 administration together with TGFβ1, ascorbic acid and insulin (supplement combination G, see table 1) raised 
chondrocyte outcome to 57.03%.Page 7 of 15
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Quantitative real-time PCR analysis revealed a slight up-
regulation of adipocyte-specific genes (ADD1, aP2, C/
EBPα, GLUT-4, LPL, PPARγ and SCD1) on day 30 in most
of the supplement combinations used for induction of
chondrocyte differentiation (fig. 7B,C). Supplement com-
bination G, which was the most successful for inducing
chondrocyte differentiation suppressed adipocyte differ-
entiation. GLUT-4 was most up-regulated in combina-
tions B and C, whereas combinations E and B induced a
increase in LPL expression compared to our chondrocyte
differentiation protocol.
Discussion
In this study, we demonstrate an improved method for
driving ES cells to a cartilaginous fate when stimulated
with BMP-2 and TGFβ1. In the early phase of differentia-
tion, BMP-2 operates by directing differentiation towards
the cartilage lineage and acting on chondroprogenitors.
During later differentiation adding mineralizing agents
can trigger hypertrophy and mineralization of the ES-
derived chondrocytes. In the embryo, maturation of
chondrocytes in the process of endochondral ossification
follows a timely regulated developmental program,
whereby cellular stages can be delimitated molecularly.
During ES cell differentiation into chondrocytes,
developmental processes follow the same pattern, as
judged by the gene expression patterns observed.
Chondrocytes, osteoblasts and adipocytes are thought to
arise from the same mesenchymal progenitor. Based on
our previous observations around VD3-induced osteogen-
esis, we have already hypothesized that during the first 5
Expression of cartilage-specific genes in the course of EB differentiation induced by BMP-2, TGFβ1, insulin and ascorbic acid (supplement combination G, table 1)Figur  4
Expression of cartilage-specific genes in the course of EB differentiation induced by BMP-2, TGFβ1, insulin and ascorbic acid 
(supplement combination G, table 1). (A) Aggrecan, collagen type II A and B and link protein, biglycan and decorin. (B) Scleraxis 
and Sox9. Results show induction factors of expression obtained by quantitative RT-PCR and normalized to GAPDH expres-
sion in comparison to corresponding spontaneously differentiated controls, which were set as 1 (mean ± standard deviation, n 
= 3 independent experiments, 20 EBs each).Page 8 of 15
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which then are susceptible to the VD3 treatment [18].
Treatment of the cultures with TGFβ1 at days 3–5 may aug-
ment the number of mesenchymal progenitors, as TGFβ1
is thought to inhibit the proliferation of most cells, but to
stimulate some mesenchymal cells such as osteoblasts
and chondrocytes [8]. It was not surprising to see adi-
pocytes develop in many of our cultures, as they represent
another member of the TGFβ1 promoted mesodermal
lineage.
The gain of adipose characteristics in culture is hall-
marked by: a) the appearance of cytoplasmic lipid
droplets, b) the acquisition of insulin sensitivity with
regard to glucose uptake (GLUT4) and c) the expression
and secretion of numerous bioactive molecules [5]. All of
Degree of osteogenesis in cultures treated with chondroinducing medium (BMP, supplement combination G), osteoinducing m dium (VD3 as described in ref. 18) and con rol ES medium (ctrl)Figur 5
Degree of osteogenesis in cultures treated with chondroinducing medium (BMP, supplement combination G), osteoinducing 
medium (VD3 as described in ref. 18) and control ES medium (ctrl). Osteoblast phenotype and mineralization could be 
increased in chondrocyte cultures by adding VD3 to chondroinducing supplements at day 20 (BMP+VD3). (A) Extent of miner-
alization as measured by Ca2+ content. **P < 0.01; ***P = 0.001. (B) RT-PCR for chondrocyte-specific and osteoblast-specific 
marker genes as well as Collagen X as a marker for the hypertrophic state of chondrocytes. (C) Morphology as seen in phase 
contrast. Black appearing cells were identified as being mineralized osteocalcin expressing osteoblasts previously [18]. No such 
cells can be seen in control (ctrl) and chondrocyte (BMP) but in osteoblast (VD3) and rescued osteoblast cultures (BMP+VD3).Page 9 of 15
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the EBs treated with BMP-2, TGFβ1, insulin and ascorbic
acid. Indeed, a future challenge for improving adipogenic
cultures will be the discovery of regulatory pathways in
adipogenesis. Once identified, such pathways may be
antagonized in order to enhance ES differentiation into
chondrocytes.
During the revision of this paper, a study was published
describing that the overexpression of the sox triad, namely
Sox9, Sox5 and Sox6, markedly increased chondrocyte
marker gene expression (collagen type 2, aggrecan) in ES
cells within 3 days [29]. Here, TGFβ1, BMP-2, IGF-1 and
FGF-2 had no affect on the immediate regulation of these
genes. In our differentiation system, Sox9 is elevated very
early during differentiation at day 5 (data not shown)
underlining its role as an early controller of chondrogen-
esis. We have shown here that BMP-2 regulates later
processes in cartilage development. Marker gene expres-
sion levels reached upon overexpression of the Sox trio do
not meet the levels we have observed in this study, sug-
gesting that Sox9 may be necessary but not sufficient do
direct all progenitors to the chondrocytic lineage.
Earlier this year, another study portrayed chondrogenesis
in ES cells using encapsulation in alginate [26]. The usage
of a 3D culture system led to an increase in Col II and
aggrecan expression of about 1.5- to 2-fold above the reg-
ular 2D system of plating EBs. Comparing those values to
the 80- to 90-fold up-regulation described here, it is clear
that three-dimensional signals also need to be
incorporated into chondrocyte differentiations to increase
differentiation efficiency.
Articular cartilage has been refractory to repair following
degeneration. Despite its limited capacity to self-repair,
cartilage is replete with cells capable of undergoing
mitotic division [30]. Current hypotheses suggest that
Dependence of genes expressed in cartilage tissue on BMP-2 with and without vitamin D3 (VD3)Figure 6
Dependence of genes expressed in cartilage tissue on BMP-2 with and without vitamin D3 (VD3). All cultures contained β-glyc-
erophosphate [10 mM] and ascorbic acid [50 µg/ml]. Mean ± SD of independent triplicates was quantified by qPCR and is nor-
malized to GAPDH expression. Controls were set as 1. **P < 0,01; ***P = 0,001. OCN = osteocalcin, BSP = bone sialoprotein, 
Cbfa1 = Core binding factor alpha, ALP = alkaline phosphatase, OPN = osteopontin, ONT = osteonectin, Col1 = Collagen 
type I. Concentrations of BMP-2 up to 100 ng/ml do not lead to osteoblast-specific expression levels that are reached with VD3 
only. 100 ng/ml BMP-2 plus VD3 given together early during differentiation can significantly up-regulate osteoblast genes. How-
ever, when VD3 is administered later (d20) in combination with BMP-2, osteoblast gene expression is almost restored.Page 10 of 15
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Characterization of ES-derived adipocytes. (A) Oil-Red-O staining of lipid droplets in ES-derived adipocytes. Bar = 42 µm. (B, 
C) Influence of BMP-2 alone and in combination with TGFβ1, insulin and ascorbic acid (see table 1) on expression of adipocyte-
specific genes. Quantitative RT-PCR was performed on 30 day old EBs. Expression of genes of interest was normalized to 
GAPDH and compared to untreated controls. Values show means ± standard deviations on n = 3 independent experiments. *P 
< 0.1; **P < 0.01; ***P = 0.001.Page 11 of 15
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expansion and differentiation or that there is a limit in the
bioactive molecules, which support chondrogenesis
[31,32]. Engineering bone or cartilage usually requires the
handling of autologous cells. Cells are released from the
ECM using collagenase and hyaluronidase. However, the
small number of available progenitors, within the tissue
can be problematic [33]. Moreover, the ability of these
harvested cells to proliferate is limited in the elderly,
where most degenerative joint disorders occur. The out-
come of conventional surgical treatment including joint
resurfacing or biological autografts has been unsatisfac-
tory following long-term evaluation [34]. This failure is
caused by insufficient repair resulting in the formation of
mechanically inadequate resident fibrocartilage. These
disappointing results and the limited therapeutic oppor-
tunities have led investigators to focus on more
appropriate bioregenerative tissue engineering
approaches, which could be specifically tailored for a
patient's needs.
Pluripotent ES cells are now being contemplated as a new
cell source for tissue engineering since they are the most
multifaceted cells amongst all stem cells. While their
pluripotency offers a huge potential for cell therapies
directed against a wide spectrum of degenerative diseases
that are ineffectively treated by traditional approaches, it
also poses challenge for controlling developmental fate in
the recipient. Understanding the developmental pathways
regulating ES cell differentiation, will enable the creation
of a cell source that can be manipulated to correct for a
particular defect.
This study was designed to improve upon the number of
differentiated cells needed for the in vitro development of
functional cartilage as this represents a first critical step in
applying ES cells clinically. Additionally, the presented in
vitro model of chondrogenesis may be useful for in vitro
embryotoxicity tests [27] as also serve as a new tool in
identifying molecular pathways that underlie chondro-
genesis. Compared to other in vitro models of chondro-
genesis, this model incorporates all steps of development
beginning with a pluripotent, uncommitted cell and thus
might further our understanding of normally unamenda-
ble stages of development.
Conclusions
This study was particularly designed to improve chondro-
cyte yields from ES cells by investigating the effect of
higher BMP-2 concentrations and the complementary
effects of TGFβ1, insulin and ascorbic acid. By examining
gene expression responses and cell sorting for GFP-
expressing chondrocytes, we demonstrate that using a
higher concentration of BMP-2 in combination with
appropriate co-factors, we can significantly enhance ES
cell derived chondrogenesis compared to known proto-
cols. In addition, we document that ES-derived chondro-
cytes behave naturally as they undergo hypertrophy.
We show that EBs supplemented with BMP-2 also result in
a small amount of adipogenesis in vitro. This observation
is consistent with knowledge that adipocytes, chondro-
cytes and osteoblasts arise from the same mesenchymal
ancestor. Accordingly, in the future, it will be necessary to
understand how to discriminate these populations for
cytotherapeutic applications. At this time, the presented in
vitro model allows the study of mechanisms involved in
BMP-2 induced chondrogenesis, osteogenesis and
adipogenesis.
Methods
Cell culture and differentiation of embryonic stem cells
Cells of the mouse ES cell line D3 (American Type Culture
Collection, Rockville, Maryland, USA) were kept in per-
manent culture as described [35,18] with the additive
Leukemia Inhibitory Factor (1000 U/ml, Gibco Life Tech-
nologies, Karlsruhe, Germany). Differentiation was initi-
ated in hanging drops. Cells condensed to form EBs,
which were transferred on day 3 into suspension culture.
At day 5, EBs were plated into 24-well tissue culture pri-
maria plates (Falcon, Heidelberg, Germany). The effects
of BMP-2 [2 or 10 ng/ml], TGFβ1 [2 ng/ml], insulin [1 µg/
ml] and ascorbic acid [50 µg/ml] in various combinations
on the differentiation of chondrocytes were examined.
Medium was changed every second day.
Alcian blue staining
Proteoglycans secreted by ES-cell derived chondrocytes
were stained with Alcian blue. Cultures were fixed in 2.5%
glutaraldehyde, 25 mM sodium acetate, 0.4 M MgCl2 con-
taining 0.05% Alcian blue for 48 h. Wash steps in 3% ace-
tic acid, 3% acetic acid/25% ethanol and 3% acetic acid/
50% ethanol reduced unspecific binding of the dye.
Metachromatic test with 1.9-dimethylmethylenblue
Proteoglycan content of differentiated cultures was deter-
mined with the DMMB-assay [36]. Proteoglycans were
extracted in 4 M guanidin-HCl/0.05 M sodium acetate
(pH 5.8) containing 100 mM 6-amino-caproic acid, 10
mM EDTA, 5 mM benzamidine/HCl, 10 mM N-ethyl-
maleimide, 0.4 mM pepstatin, 1 mM PMSF and 1 µg/ml
soy bean trypsin inhibitor for 48 h at 4°C. Non-com-
pletely digested cells were separated from the lysate by
centrifugation. Lysate was mixed with DMMB reagent
(0.16% w/v DMMB in 0.2% formic acid containing 2 mg/
ml sodium formate, pH 3.5) and changes in absorption
were detected at 535 nm in a spectrophotometer. Concen-
tration of proteoglycans in samples was read against a
standard curve of chondroitin sulfate C.Page 12 of 15
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Embryoid bodies were differentiated to the chondrocyte
lineage with BMP-2, TGFβ1, insulin and ascorbic acid and
fixed on day 32 with ice-cold methanol:aceton (7:3) at -
20°C for 10 min. For staining with anti-collagen type II
(Chemicon, MAB 8887) cultures were digested with pep-
sin for 15 min at 37°C. Staining with anti-adult proteogly-
can (Chemicon MAB 2015) was performed after a 1 h
digest with chondroitinase ABC at room temperature.
Cells were overlaid with the appropriate dilution of the
first antibodies in PBS, 10% FCS at 4°C over night. The
corresponding secondary antibody, an AlexaFluor 488
goat anti-mouse IgG (H+L), F(ab')2 fragment (A-11006,
Molecular Probes, Leiden, The Netherlands) was incu-
bated with the cells for 2 h at room temperature. Cultures
were observed in a Leica Fluovert FU fluorescent micro-
scope (Leitz, Wetzlar) with an excitation wavelength of
495 and an emission wavelength of 519 nm.
RNA isolation, RT-PCR and real-time quantitative RT-PCR
Total RNA was isolated from 20 EBs per probe using the
RNeasy Midi Kit (Qiagen, Hilden, Germany) according to
the manufacturer's instructions with on-column DNase I
digestion. The amount of RNA was determined using the
RiboGreen™ RNA quantitation reagent and kit (Molecular
Probes). 275 ng total EB RNA was used as a template for
cDNA synthesis with Superscript II (Invitrogen, Paisley,
Scotland) as described [27,35] in a total reaction volume
of 25 µl. 5 µl aliquots of the first strand reaction were used
for amplification performed with specific primers (see
table 2). Primer sequences for osteoblast-specific genes
and PCR conditions have been described previously [18].
PCR products were visualized on 3% agarose gels contain-
ing 0.1 µg/ml ethidium bromide. Quantitative real-time
PCR analysis was performed in an ABI Prism® 7700
Sequence Detector. The accumulation of reaction
products during PCR was monitored by measuring the
increase in fluorescence caused by the binding of SYBR®
Green (Applied Biosystems, Perkin Elmer, Weiterstadt,
Germany) to double-stranded DNA. Expression analysis
of collagen type II A and B was done in the same PCR run
with two differently labelled probes specific for either the
A isoform (5'-CGAGATCCCCTTCGGAGAGTGCTGT-3'/
VIC) or the B isoform (5'-CCAGGATGCCCGAAAATTAG-
GGCCAA-3'/FAM) [27]. Reaction mixtures were set up as
suggested by the manufacturer containing either SYBR
Green or probes for collagen type II. Following a 10 min
Taq Polymerase activating step at 95°C, the reactions were
cycled by denaturing at 94°C for 30 s and annealing and
elongation for 30 s at the corresponding temperatures
(table 2). Target gene CT-values were standardized against
GAPDH expression and induction of expression in treated
EBs was normalized to control EBs. Primer sequences for
murine GAPDH were 5'-GCACAGTCAAGGCCGAGAAT-
3' and 5'-GCCTTCTCCATGGTGGTGAA-3' (Ta = 60°C).
Quantification of chondrocyte yield by FACS
The GFP expressing plasmid pEGFP-1 (Clontech) under
the control of the Aggrecan promotor (kind gift of John R.
Matyas) was stably transfected into D3 ES cells using Inv-
itrogen's Effectene system followed by neomycin selec-
tion. Genomic integration of the reporter was analyzed by
RT-PCR with specific GFP primers (data not shown). ES
cells were differentiated along the chondrocyte lineage,
trypsinized into a single cell suspension and subjected to
fluorescence-activated cell sorting on day 32 using a FACS
Calibur instrument and the CellQuest software from Bec-
ton Dickinson (Germany). Ten thousand events were
registered per sample and analysis of whole cells was
performed using appropriate scatter gates to avoid cellular
debris and aggregates.
Table 2: Sequences and annealing temperatures for the primer 
sets used in RT-PCR
Gene Primer sequence Tm in °C
Chondrocyte-
specific
Aggrecan 5'-GATCTGGCATGAGAGAGGCG-3'
5'-GCCACGGTGCCCTTTTTAC-3'
61
Collagen type II 5'-GCTGCTGACGCTGCTCATC-3'
5'-GGTTCTCCTTTCTGCCCCTT-3'
60
Collagen type X 5'-CAAGCCAGGCTATGGAAGTC-3'
5'-AGCTGGGCCAATATCTCCTT-3'
60
Link protein 5'-TTCTGGGCTATGACCGCTG-3'
5'-AGCGCCTTCTTGGTCGAGA-3'
60
Biglycan 5'-CATGACAACCGTATCCGCAA-3'
5'-ATTCCCGCCCATCTCAATG-3'
60
Decorin 5'-ATGACCCTGACAATCCCCTG-3'
5'-CCCAGATCAGAACACTGCACC-3'
60
Scleraxis 5'-GGACCGCAAGCTCTCCAAG-3'
5'-ACCCACCAGCAGCACATTG-3'
62
Sox9 5'-GCAGACCAGTACCCGCATCT-3'
5'-CTCGCTCTCGTTCAGCAGC-3'
62
Adipocyte-
specific
ADD1 5'-CAGTGACTCTGAGCCCGACA-3'
5'-ATGCCTCGGCTATGTGAAGG-3'
61
PPARγ 5'-ATCATCTACACGATGCTGGCC-3'
5'-CTCCCTGGTCATGAATCCTTG-3'
59
SCD1 5'-ACACCATGGCGTTCCAAAAT-3'
5'-CGGCGTGTGTTTCTGAGAACT-3'
61
C/EBPα 5'-CGCAAGAGCCGAGATAAAGC-3'
5'-GCGGTCATTGTCACTGGTCA-3'
60
GLUT-4 5'-ATGGCTGTCGCTGGTTTCTC-3'
5'-ACCCATAGCATCCGCAACAT-3'
59
AP2 5'-TGATGCCTTTGTGGGAACCT-3'
5'-GCAAAGCCCACTCCCACTT-3'
58
acrp30 5'-AAGAAGGACAAGGCCGTTCTC-3'
5'-GAGGAGCACAGAGCCAGAGG-3'
60
LPL 5'-CCAATGGAGGCACTTTCCAG-3'
5'-CCACGTCTCCGAGTCCTCTC-3'
60
Forward primer sequence is depicted from the 5' to the 3' end 
followed by the reverse primer. The appropriate annealing 
temperature for each set is given as Tm in °C.Page 13 of 15
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Cells were washed with PBS and without any fixation
directly overlaid with Oil-red-O working solution (0.18%
Oil-Red-O dye/60% propanol) After a staining period of
15 minutes, ES cell cultures were rinsed in distilled water
until desired colour was achieved.
Statistical analysis
Data analysis was performed with ONE-WAY ANOVA on
n = 3 experiments using SigmaStat version 2.03 (SPSS Inc.,
San Rafael, CA, USA).
List of abbreviations
ADD1 Adipocyte determination- and differentiation-
dependent factor 1
aP2 Fatty acid-binding protein
BMP Bone Morphogenetic Protein
Cbfa1 Core binding factor alpha 1
C/EBP CCAAT/enhancer-binding protein
Col Collagen
DMMB Dimethylmethylenblue
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ES embryonic stem
EB embryoid body
FCS Fetal calf serum
FGF Fibroblast growth factor
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GLUT4 Glucose transporter 4
IGF Insulin-like growth factor
PPAR Peroxisome proliferator-activated receptor
SCD Steroyl CoA desaturase
Sox Sry-related high mobility group box
TGFβ Transforming Growth Factor beta
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